Cadrenal Therapeutics, Inc. (CVKD)
NASDAQ: CVKD · IEX Real-Time Price · USD
0.430
-0.010 (-2.21%)
At close: Jul 19, 2024, 4:00 PM
0.490
+0.060 (13.95%)
Pre-market: Jul 20, 2024, 9:28 AM EDT
Cadrenal Therapeutics Stock Forecast
CVKD's stock price has decreased by -67.42% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 2 analysts with 12-month price forecasts for CVKD stock have an average target of 3.50, with a low estimate of 3.00 and a high estimate of 4.00. The average target predicts an increase of 713.95% from the current stock price of 0.43.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jun 6, 2024.
Analyst Ratings
The average analyst rating for CVKD stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $3 | Strong Buy | Reiterates | $3 | +597.67% | Jun 6, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $3 | Strong Buy | Reiterates | $3 | +597.67% | May 9, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $3 | Strong Buy | Reiterates | $3 | +597.67% | Mar 14, 2024 |
| Noble Capital Markets | Noble Capital Markets | Buy Initiates $4 | Buy | Initiates | $4 | +830.23% | Dec 18, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $3 | Strong Buy | Initiates | $3 | +597.67% | Nov 20, 2023 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.37
from -0.62
EPS Next Year
-0.35
from -0.37
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | 6.6M | 95.3M |
| Avg | n/a | n/a | n/a | 3.2M | 54.8M |
| Low | n/a | n/a | n/a | n/a | 16.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 2,864.7% |
| Avg | - | - | - | - | 1,606.7% |
| Low | - | - | - | - | 412.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.23 | -0.23 | -0.22 | -0.51 | -0.28 |
| Avg | -0.37 | -0.35 | -0.35 | -0.50 | -0.28 |
| Low | -0.49 | -0.45 | -0.47 | -0.48 | -0.26 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.